FI924848A - Triazaspirodekanon-metylkromaner - Google Patents

Triazaspirodekanon-metylkromaner Download PDF

Info

Publication number
FI924848A
FI924848A FI924848A FI924848A FI924848A FI 924848 A FI924848 A FI 924848A FI 924848 A FI924848 A FI 924848A FI 924848 A FI924848 A FI 924848A FI 924848 A FI924848 A FI 924848A
Authority
FI
Finland
Prior art keywords
medicaments
triazaspirodekanon
metylkromaner
triazaspirodecanones
triazaspirodecanonemethylchromans
Prior art date
Application number
FI924848A
Other languages
English (en)
Other versions
FI924848A0 (fi
Inventor
Hans-Georg Heine
Rudolf Schohe-Loop
Thomas Glaser
Vry Jean Marie Viktor De
Wolfgang Dompert
Henning Sommermeyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI924848A0 publication Critical patent/FI924848A0/fi
Publication of FI924848A publication Critical patent/FI924848A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI924848A 1991-10-28 1992-10-26 Triazaspirodekanon-metylkromaner FI924848A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4135473A DE4135473A1 (de) 1991-10-28 1991-10-28 Triazaspirodecanon-methylchromane

Publications (2)

Publication Number Publication Date
FI924848A0 FI924848A0 (fi) 1992-10-26
FI924848A true FI924848A (fi) 1993-04-29

Family

ID=6443565

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924848A FI924848A (fi) 1991-10-28 1992-10-26 Triazaspirodekanon-metylkromaner

Country Status (19)

Country Link
US (1) US6060482A (fi)
EP (1) EP0539803B1 (fi)
JP (1) JP3257708B2 (fi)
KR (1) KR930007945A (fi)
AT (1) ATE175414T1 (fi)
AU (1) AU650792B2 (fi)
CA (1) CA2081256A1 (fi)
CZ (1) CZ322492A3 (fi)
DE (2) DE4135473A1 (fi)
DK (1) DK0539803T3 (fi)
ES (1) ES2125879T3 (fi)
FI (1) FI924848A (fi)
GR (1) GR3029450T3 (fi)
HU (1) HUT64068A (fi)
IL (1) IL103546A0 (fi)
MX (1) MX9205869A (fi)
NO (1) NO923974L (fi)
TW (1) TW208010B (fi)
ZA (1) ZA928290B (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
WO2001039723A2 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
WO2003040382A1 (fr) * 2001-11-09 2003-05-15 Kaneka Corporation Procede de production d'un derive de chromane optiquement actif et d'un produit intermediaire
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
BR0306309A (pt) * 2002-09-09 2004-10-19 Janssen Pharmaceutica Nv Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1
WO2005036104A1 (en) * 2003-10-16 2005-04-21 Collier William R Fluid level detector and alarm apparatus
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
EP2102206B1 (en) * 2006-11-28 2015-04-08 Janssen Pharmaceutica NV Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
WO2008124209A1 (en) * 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826835A (en) * 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
US4749702A (en) * 1985-04-15 1988-06-07 Janssen Pharmaceutica N. V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4826848A (en) * 1985-04-15 1989-05-02 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination

Also Published As

Publication number Publication date
EP0539803B1 (de) 1999-01-07
JPH05222040A (ja) 1993-08-31
CA2081256A1 (en) 1993-04-29
ATE175414T1 (de) 1999-01-15
GR3029450T3 (en) 1999-05-28
CZ322492A3 (en) 1993-07-14
ES2125879T3 (es) 1999-03-16
DE59209607D1 (de) 1999-02-18
DK0539803T3 (da) 1999-08-30
HUT64068A (en) 1993-11-29
NO923974L (no) 1993-04-29
EP0539803A1 (de) 1993-05-05
AU650792B2 (en) 1994-06-30
TW208010B (fi) 1993-06-21
DE4135473A1 (de) 1993-04-29
ZA928290B (en) 1993-05-04
MX9205869A (es) 1993-04-01
JP3257708B2 (ja) 2002-02-18
AU2626592A (en) 1993-04-29
NO923974D0 (no) 1992-10-13
FI924848A0 (fi) 1992-10-26
HU9203382D0 (en) 1993-01-28
IL103546A0 (en) 1993-03-15
US6060482A (en) 2000-05-09
KR930007945A (ko) 1993-05-20

Similar Documents

Publication Publication Date Title
FI925549A0 (fi) Nya azaheterocyklylmetyl-kromaner
TW289020B (fi)
FI921087A0 (fi) Nya estrar av tienylkarboxylsyror och aminoalkoholer, deras kvaterniseringsprodukter och framstaellning och anvaendning av naemnda foereningar.
NL300181I1 (nl) N-(pyrroloÄ2,3-dÜpyrimidine-3-ylacyl)-glutaminezuurderivaten.
FI942161A (fi) Menetelmä 5-metyyli-tetrahydrofoolihapon erottamiseksi
FI924848A (fi) Triazaspirodekanon-metylkromaner
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
NO941958L (no) Fremstilling av substituerte piperidiner
NO930029L (no) 4,13-dioxabicyklo(8.2.1)tridecenonderivater, fremgangsmaater og mellomprodukter for deres fremstilling, og legemidler inneholdene disse forbindelser
ATE72434T1 (de) Pyrazolsulfonamide-derivate, verfahren zu deren herstellung und diese enthaltende herbizide mittel.
NO881997D0 (no) Nye 4-benzyl-1-(2h)-ftalazinonderivater med en aminosyrerest.
DE3881866D1 (de) System zur belichtungsadressierung hoher aufloesung mit grobaufgeloestem belichtungsfeld.
AU588065B2 (en) Substituted diazaoxaspirodecanes, preparation thereof and use thereof as stabilizers for polymers
FI924477A0 (fi) Foerfarande foer diastereoselektiv reduktiv pinakolkoppling av homochirala a-aminoaldehyder
DE68906049D1 (de) Benzocyclohexan- und benzocycloheptan-derivate und deren salze, verfahren und zwischenprodukte zu deren herstellung, deren verwendung als heilmittel und diese enthaltende zusammensetzungen.
PT87563A (pt) Process for the preparation of vinylcephalosporins useful as medicaments
MX9202930A (es) Procedimiento microbiologico para preparar acido 5-hidroxi-pirazincarboxilico.
ITMI920460A0 (it) Procedimento per produrre l-lisina mediante fermentazione
ATE157081T1 (de) Beta-phenylisoserin-(2r,3s), ihre salze, herstellung und verwendung
PT746556E (pt) Compostos triciclicos com afinidade para o receptor 5-ht1a
DK0478941T3 (da) Lægemidler indeholdende substituerede 2-cyclohexen-1-yl-amin-derivater og deres anvendelse til bekæmpelse af sygdomme
DK0547502T3 (da) Hærdeligt bindemiddel og fremgangsmåde til fremstilling deraf
NO933465L (no) Legemidler inneholdende 1,5,6,7-tetrahydro-4-indazol-4-on-derivater, nye 1,5,6,7-tetrahydro-4-indazol-4-on-derivater, og fremgangsmåte for deres fremstilling
ATE52028T1 (de) Verwendung eines diamins zur herstellung eines erythrozyten-weichmachers.
ATE62688T1 (de) Benzylaminoaryl-dihydropyridinelactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.